---
title: 'Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination
  with carboplatin in children with advanced malignancies: Arm C of the AcSÃ©-ESMART
  trial'
date: '2023-12-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38051741/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231206170903&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Adavosertib-carboplatin combination exhibited significant
  hematologic toxicity. Activity signals and identified potential biomarkers suggest
  further studies with less hematotoxic DNA damaging therapy in molecularly enriched
  pediatric ...'
disable_comments: true
---
CONCLUSIONS: Adavosertib-carboplatin combination exhibited significant hematologic toxicity. Activity signals and identified potential biomarkers suggest further studies with less hematotoxic DNA damaging therapy in molecularly enriched pediatric ...